12/04/2026
𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗪𝗶𝘁𝗵 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝗟𝗼𝘄 𝗕𝗮𝗰𝗸 𝗣𝗮𝗶𝗻 𝗪𝗶𝘁𝗵𝗼𝘂𝘁 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗗𝗶𝘀𝗸 𝗗𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗘𝘅𝗵𝗶𝗯𝗶𝘁 𝗚𝘂𝘁 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲 𝗗𝘆𝘀𝗯𝗶𝗼𝘀𝗶𝘀
As physical therapist and clinical exercise physiologists, we are constantly looking for the "why" behind those persistent cases where a patient’s MRI doesn't match their level of pain and disability.
📘 A brand-new study by Sima et al. (2026, https://onlinelibrary.wiley.com/doi/10.1002/jsp2.70174) offers a compelling look at the "gut-disk axis" as a potential driver for chronic low back pain (LBP). Historically, we’ve relied on imaging to find structural culprits, but as Sima and Diwan (2025, https://pubmed.ncbi.nlm.nih.gov/39867670/) point out, many patients lack an easily identifiable surgical pathology. This research bridges that gap by investigating how our internal ecosystem might be fueling spinal inflammation from the inside out.
𝗧𝗵𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗚𝘂𝘁-𝗗𝗶𝘀𝗸 𝗔𝘅𝗶𝘀
The study compared 28 chronic LBP patients without advanced disk degeneration to 28 healthy, matched controls. The researchers built upon the work of Li et al. (2022, https://pubmed.ncbi.nlm.nih.gov/35286474/), who first proposed the "gut-disk axis"—a pathway where intestinal dysbiosis leads to systemic inflammation that eventually sensitizes the nerves around our spinal disks. This theory is supported by earlier findings from Shmagel et al. (2019), who found a significant association between dysbiosis and the presence and severity of musculoskeletal pain, particularly in the lower back.
📊 What Sima et al. (2026) discovered was a significant drop in alpha diversity (the richness of the microbiome) in LBP patients. This is a hallmark of dysbiosis also noted by Nitert et al. (2020, https://pmc.ncbi.nlm.nih.gov/articles/PMC7492308/) in overweight back pain cohorts. Specifically, the LBP group showed a depletion of Bacteroidota and Parabacteroides. These "good" bacteria produce short-chain fatty acids (SCFAs), which Agus et al. (2021, https://pubmed.ncbi.nlm.nih.gov/33272977/) and Ney et al. (2023, https://pubmed.ncbi.nlm.nih.gov/36977462/) have shown are vital for maintaining the gut barrier and suppressing pro-inflammatory cytokines like IL-17.
𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀?
When these protective bacteria are lost, "bad" players like Proteobacteria and Desulfobacterota take over. This shift increases intestinal permeability allowing endotoxins to enter the bloodstream. Once these toxins reach the intervertebral disk, they can trigger the infiltration of nociceptive fibers. This process, supported by research from Larsen (2017, https://pubmed.ncbi.nlm.nih.gov/28542929/) on Prevotella-induced inflammation and Cheng et al. (2013, https://pubmed.ncbi.nlm.nih.gov/23680281/) on Th17 cell frequency, might explain the pathogenesis and pain severity of IVD degeneration in part.
💡 Ultimately, this suggests that our role in the clinic might extend beyond biomechanics. Emerging evidence hints that therapies we already use, like exercise and psychologically informed practice, might actually help by enhancing microbial diversity. This study reinforces that we need a holistic, biopsychosocial approach to back pain that considers systemic inflammation and perhaps even microbiome-targeted interventions to get our patients moving better.